

Hebei,China

2381089-83-2

COA,GMP,CQC,SGS

Xinzhou

100g

1kg/bag

within 3 days

Tirzepatide GLP-1 Peptide 5mg 10mg Vial With 99% Purity Cas 2381089-83-2

Basic Information

- Place of Origin:
- Brand Name:
- Certification:
- Model Number:
- Minimum Order Quantity:
- Price: Discuss in detail
- Packaging Details:
- Delivery Time:
- Payment Terms: Paypal, Western Union, Bitcoin payment, Xtransfer, L/C, T/T, MoneyGram,
- Supply Ability:
- 500kg/week



Product Specification

•	Highlight:	99% Purity GLP-1 Peptide, Tirzepatide GLP-1 Peptide, Tirzepatide GLP-1 10mg Vial
 Specification: 		As Your Requirement
•	Sample:	Available
•	Recommended Use Level:	100-1000PPM
•	Msds:	Avaliable
•	Cas:	Tirzepatide
• /	Assay:	99%Min
•	Product Name:	2381089-83-2



Our Product Introduction

Products Description

Semaglutide is a new generation GLP-1 (glucagon-like peptide-1) analogues. Semaglu.tide is a long-acting dosage form based on the basic structure of liraglu.tide, which is more effective in the treatment of type 2 diabetes mellitus. Compared with lilarlu.tide, somalutide has a longer aliphobic chain and an increased hydrophobicity, but somalutide is modified with a short chain of PEG, and its hydrophilicity is greatly enhanced.PEG modification can not only tightly bind to albumin, cover up the DPP-4 enzymatic hydrolysis site, but also reduce renal excretion, prolong the biological half-life, and achieve the effect of long circulation.

Tirzepat.ide (LY3298176) is a glucose-dependent in sulin nutrient polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor dual agonist under development for the treatment of type 2 diabetes mellitus. Tirze.patide (LY3298.176) was significantly more effective in glycemic control and weight loss than dura lutide.

Retatru.tide is the newest GLP-1R agonist and was approved by the FDA as a once-weekly injection for the treatment of T2DM in late 2017. The peptide is chemically similar to semagl.utide,tirzepat.ide, with the inclusion of two structural modifications (Lau, Bloch, et al., 2015). The first is the replacement of Gly with the non-proteinogenic amino acid 2-aminoisobutyric acid (Aib) at position 2. The second is the attachment of octadecanoic diacid to the side chain of Lys-26 through a short polyethylene glycol (PEG) spacer and a γ-glutamic acid linker. The amino acid substitution renders the peptide more resistant to DPP-4 compared to liragl.utide, and the presence of the 18-carbon fatty acid moiety results in a high binding affinity for serum albumin, which translates to a half-life of approximately 7 days in humansRaw Powder Lira.glutide is a clear, colorless solution. The dosage form is subcutaneous injection. After more than 10 years of research and development, Peptide Liragl.utide has many effects such as promoting islet cell regeneration, lowering blood sugar, reducing weight and protecting the cardiovascular system. The brand name Victoza is used to treat type 2 diabetes, and the brand name Liragl.utide is used to treat chronic obesity as a supplement for diet control and physical exercise

semag CAS:102-97-6 image:





Company Profile

Xingtai Xinzhou Technology Co., LTD.

Xingtai Xinzhou Technology Co., Ltd. was established in 2022 with strong research and development capabilities and superb synthesis technology, as well as advanced quality control measures. Effectively promote the joint venture and cooperation with the major enterprises, manufacturers, with the idea of industrial development to serve the society and the majority of users. We always adhere to the market demand as the orientation, constantly synthesizing new high-tech chemical products and medical intermediates, mainly exported to the United States, India, South Africa, Nigeria and other countries and regions, has a wealth of export experience, to ensure transportation safety, can let each customer as soon as possible to safely receive the goods.



Certificate



Federa Ups ZHL TNT



